We recently published 10 Stocks Jim Cramer Talked About. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer talked ...
Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...
Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped ...
We recently published a list of Jim Cramer’s Thoughts on These 5 Stocks. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer ...
Pfizer (PFE) has seen its stock fall to its lowest level in 13 years as pressure from falling blockbuster drug sales weighs on performance. CEO Bourla maintains supporting the dividend is a high ...
ARLETA, CA - AUGUST 02: Fernandeno Tataviam Band of Mission Indians, as part of its participation in the Medi-Vaxx Program of the San Fernando Valley, with El Proyecto del Barrio, Los Angeles Mission ...
Zacks Investment Research on MSN
Pfizer (PFE) ascends while market falls: Some facts to note
In the latest close session, Pfizer (PFE) was up +1.63% at $25.56. This move outpaced the S&P 500's daily loss of 0.53%. On the other hand, the Dow registered a loss of 0.09%, and the ...
Pfizer crushed Q2 estimates with $14.7B revenue and $0.78 EPS, signaling a powerful turnaround driven by broad-based growth and operational excellence. A successful cost realignment program drove the ...
Zacks Investment Research on MSN
Pfizer (PFE) outpaces stock market gains: What you should know
In the latest close session, Pfizer (PFE) was up +1.12% at $25.18. The stock outpaced the S&P 500's daily gain of 0.19%. Meanwhile, the Dow experienced a rise of 0.66%, and the technology-dominated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results